Le Lézard
Classified in: Health, Business
Subject: ATY

Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors - Contact The Gross Law Firm


NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).

Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=128948&from=4

CLASS PERIOD: December 12, 2023 to October 31, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE: March 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=128948&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 25, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 09:15
IKS Health, a global leader in care enablement solutions, proudly announces the launch of Scribble Now, the latest addition to the IKS Health Scribble Suite, at ViVE 2025, February 16-19. This real-time documentation solution completes the industry's...

at 09:13
U.S. Renal Care (USRC), the fastest-growing dialysis provider in the nation and the industry leader in clinical quality and patient experience, is proud to announce a new employee benefit program supporting frontline team members in becoming future...

at 09:13
The number of U.S. product recalls remained high during 2024 with more than 3,200 events recorded for the second consecutive year. According to Sedgwick brand protection's 2025 U.S. State of the Nation Recall Index report, the 3,232 recalls across...

at 09:10
ForSight Robotics, the pioneer in ophthalmic robotic surgery, announced today that Dr. Fred Moll, the founder of Intuitive Surgical, has joined its Board of Directors. Intuitive Surgical is the company behind the da Vinci surgical system, the first...

at 09:10
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical...

at 09:07
Submitted research has nearly doubled to a record-breaking 460 abstracts for the 9th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC). "The depth of novel insights that will be unveiled during the AOPMC showcases the...



News published on and distributed by: